Skip to main content

Prostate Cancer MEVPRO-1

Status: Open to Enrollment
Email Us To Enroll

Study Details

View study details on www.clinicaltrials.gov.

Locations

  • Santa Rosa

Clinical Trial FAQs

Information for patients and study volunteers, including frequently asked questions.

Pfizer MEVPRO-1 (C2321014) is a randomized, open-label, multi-center clinical trial evaluating whether combining the study medicine (PF-06821497) with enzalutamide is safe and effective compared to physician's choice of either second-line androgen receptor (AR) directed therapy with enzalutamide or docetaxel (chemotherapy) for treating metastatic castration-resistant prostate cancer (mCRPC) after progression on prior abiraterone acetate treatment.

The primary objective of this clinical trial is to assess the radiographic progression free survival (rPFS) of the combination of PF-06821497 plus enzalutamide versus physician's choice of enzalutamide or docetaxel.

Zeyad H. Kanaan
Zeyad H. Kanaan
Principal investigator
View Profile

Email Us to Enroll

You're leaving our site

The website you have selected is an external one located on another server. This website may contain links to third party sites. These links are provided for convenience purposes and are not under the control of Sutter Health. Do you wish to continue?